Pediatric Brain Tumors Market Report 2026

The pediatric brain tumors market size has grown strongly in recent years. It will grow from $1.4 billion in 2025 to $1.49 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to limited awareness of pediatric brain tumors, reliance on conventional therapies, low adoption of advanced imaging techniques, lack of specialized pediatric neuro-oncology centers, limited availability of targeted and immunotherapy treatments.

The pediatric brain tumors market size is expected to see strong growth in the next few years. It will grow to $1.93 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to growing incidence of pediatric brain tumors, increasing adoption of precision medicine, rising integration of ai and digital imaging in diagnostics, growing focus on personalized treatment plans, increasing funding for pediatric neuro-oncology research. Major trends in the forecast period include increasing adoption of precision medicine for pediatric brain tumors, rising integration of digital imaging and ai-based diagnostics, growing use of targeted therapies and immunotherapies, increasing focus on minimally invasive surgical techniques, rising investment in pediatric neuro-oncology research.

The increasing demand for personalized medicine is expected to drive the growth of the pediatric brain tumors market in the coming years. Personalized medicine is a healthcare approach that tailors treatments and clinical decisions based on an individual’s genetic profile, lifestyle factors, and specific health needs. Demand for personalized medicine is rising due to progress in genetic research, enhanced diagnostic capabilities, and the potential to deliver more precise and effective therapies. By customizing treatment according to a child’s tumor type, genetic mutations, and treatment response, personalized medicine enables targeted therapies that improve outcomes while minimizing damage to healthy tissue and reducing side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, compared to six approvals in 2022. Therefore, the growing adoption of personalized medicine is contributing to the growth of the pediatric brain tumors market.

Major companies operating in the pediatric brain tumors market are concentrating on the development of advanced therapies, such as type II RAF inhibitors, to strengthen targeted treatment options and improve patient outcomes. Type II RAF inhibitors are targeted therapies designed to inhibit RAF kinases, particularly mutated forms that promote tumor growth. These inhibitors specifically address abnormal RAF protein structures present in certain pediatric low-grade glioma (pLGG) subtypes, effectively blocking dysfunctional signaling pathways responsible for tumor cell growth and survival. For example, in April 2024, Day One Biopharmaceuticals, a US-based biotechnology company, announced that the U.S. Food and Drug Administration granted accelerated approval to OJEMDA (tovorafenib) for the treatment of relapsed or refractory pediatric low-grade glioma in patients aged six months and older with specific BRAF alterations. This approval marked OJEMDA as the first FDA-approved therapy targeting BRAF fusions or mutations in this patient group. The decision was based on an overall response rate of 51 percent observed in the FIREFLY-1 clinical trial, which evaluated the drug’s effectiveness for this indication. The therapy is intended for children whose brain tumors have not responded to prior treatments.

In July 2024, Ipsen, a France-based biopharmaceutical company, entered into a partnership with Day One Biopharmaceuticals to commercialize tovorafenib for pediatric low-grade glioma outside the United States. Under this collaboration, Ipsen will manage global regulatory and commercial activities for tovorafenib. Day One Biopharmaceuticals is a US-based company that develops treatments for childhood brain tumors, including OJEMDA.

Major companies operating in the pediatric brain tumors market are Bayer AG, Novartis AG, Roche Holding AG, Takeda Pharmaceutical Company, UCLA Health, Novocure, Blueprint Medicines, Oncoheroes Biosciences, Plus Therapeutics Inc., Stemline Therapeutics Inc., BrainChild Bio Inc., Seattle Children's Therapeutics, Pfizer Inc., Merck & Co Inc., Bristol Myers Squibb Company, Sanofi, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eli Lilly and Company, Day One Biopharmaceuticals Inc., Biodexa Pharmaceuticals, Cellectar Biosciences Inc., ZIOPHARM Oncology Inc., Y‑mAbs Therapeutics Inc., Neonc Technologies Inc.

North America was the largest region in the pediatric brain tumors market in 2025. The regions covered in the pediatric brain tumors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pediatric brain tumors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the pediatric brain tumors market by increasing costs of imported surgical equipment, targeted therapy drugs, and diagnostic imaging systems, particularly impacting North America and Europe. Higher import costs have delayed procurement in hospitals, clinics, and research centers. Nevertheless, tariffs have also encouraged local production of treatment devices and therapies, fostering domestic innovation and cost-optimized solutions in pediatric neuro-oncology.

The pediatric brain tumors market research report is one of a series of new reports that provides pediatric brain tumors market statistics, including pediatric brain tumors industry global market size, regional shares, competitors with a pediatric brain tumors market share, detailed pediatric brain tumors market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric brain tumors industry. This pediatric brain tumors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pediatric brain tumors are abnormal cell growths that develop in the brain or central nervous system (CNS) of children. These tumors may be benign (non-cancerous) or malignant (cancerous) and can originate in various regions of the brain or spinal cord. The primary objective of treatment is to reduce or eliminate the tumor, alleviate symptoms, and preserve cognitive and motor functions to support the child’s long-term health and development.

The major types of pediatric brain tumors include gliomas, mixed neuronal-glial tumors, embryonal tumors, choroid plexus papilloma or carcinoma, as well as tumors arising from non-neuroepithelial tissue and meningeal tumors. Gliomas represent the most common form of pediatric brain tumors, originating from glial cells and comprising several subtypes that differ in severity and often require intensive treatment due to their infiltrative nature and potential for recurrence. These tumors are managed through various treatment approaches such as surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, along with multiple diagnostic methods including imaging techniques, biopsy, neurological examinations, and lumbar puncture. They occur across different age groups, including infants, toddlers, children, and adolescents, and are addressed in a range of settings such as hospitals and clinics, medical research centers, academic institutes, and others.

The pediatric brain tumor market consists of revenues earned by entities providing services such as neuro-oncology care, rehabilitation services, psychosocial support, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The pediatric brain tumor market also includes sales of chemotherapy drugs, surgical instruments, and radiation therapy equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.